Rod MacKenzie, PhD, is chief development officer and executive vice president for Pfizer. Dr. MacKenzie leads Global Product Development, which is responsible for the clinical development and advancement of Pfizer’s pipeline of innovative medicines, as well as regulatory affairs in support of Pfizer’s R&D pipeline and portfolio of marketed therapies. He is a member of Pfizer’s executive leadership team. Dr. MacKenzie represents Pfizer on the Board of Directors for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV. He also represents Pfizer on the board of TransCelerate, a non-profit biopharmaceutical industry collaborative formed to identify and solve common drug development challenges with the end goals of improving clinical trial quality and bringing new treatment to patients faster. Dr. MacKenzie first joined Pfizer in Sandwich, UK, as a research scientist and conducted medicinal chemistry research in several disease areas. He is the co-inventor of darifenacin, brand named Enablex™. He has held numerous senior leadership positions at Pfizer in research and development, spanning areas including discovery chemistry, drug safety, and worldwide research, and has led several of Pfizer’s major R&D sites and technology centers. Dr. MacKenzie graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his PhD at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University in New York working in the area of molecular recognition with Professor W.C. Still.